PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Amphista Therapeutics to present AMX-883 data at American Society of Hematology (ASH) Annual Meeting

  • AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)
  • Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and preliminary efficiency to publish in Blood

Amphista Therapeutics Limited, a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12–15, 2026. The full abstract is available online: www.hematology.org/Meetings/Annual-Meeting/Abstracts

The data, to be presented by Dr Louise Modis, CEO, suggest BRD9 plays a critical role in acute myeloid leukaemia (AML), maintaining activity of a number of hematopoietic transcription factors. Degradation of BRD9 using AMX-883 restricts these transcription factor programmes, releasing the differentiation block and reducing the frequency of leukemic stem cells.

Presentation details:

  • Title: AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation and depletes leukemic stem cells in acute myeloid leukaemia
  • Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML. December 14, 2026, 10:30 AM – 12:00 PM
  • Room: MCCNO – Great Hall BC
  • Presentation time: December 14, 2026, 11:45 AM – 12:00 PM
  • Publication number: 762
  • Submission ID: abs26-9908

The second abstract, due to be published in the ASH Blood Supplement, highlights Amphista’s ongoing AMX-883 BRAMLIE trial1, an open label, multi-part, dose escalation and optimisation study:

  • Abstract number: abs26-2088
  • Title: A Phase 1, open-label, multi-centre study to assess the safety, pharmacokinetics and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia and high-risk myelodysplastic syndrome and in combination in participants with AML
  • Category: 600s – Hematologic Malignancy
  • Review category: 616. Acute Myeloid Leukemias: lnvestigational Drug and Cellular Therapies
  • Authors: Eytan Stein, Emma Searle, Amir Fathi, Jayastu Senapati, Justin Watts, Victoria Campbell, Jenny O’Nions, Alexander Spira, David Taussig, Paul Player, Giulia Petrone, Anthony Selwyn Stein, Lisa Butler, Patrick Kelly
  1. https://amphista.com/amphista-therapeutics-announces-first-patient-dosed-in-amx-883-phase-1-clinical-trial-for-acute-myeloid-leukemia/

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC